#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14142	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2652	649.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1718	1718	C	863	C,T,A	861,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23536	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4059	723.1	0	.	n	.	0	T695C	SNP	695	695	T	1238	1238	C	913	C,T,G,A	910,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23536	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4059	723.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1880	1880	A	979	A,C,G	976,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23536	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4059	723.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2514	2514	C	808	C,G	806,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23536	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4059	723.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3140	3140	T	830	T,C,G	827,1,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23536	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4059	723.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2588	2588	A	719	A	719	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2178	folP	852	852	100.0	folP.l15.c4.ctg.1	2185	124.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1334	1336	AGC	253;249;252	A,G;G;C,A	252,1;249;251,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5400	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3714	181.0	1	SNP	p	S91F	0	.	.	271	273	TCC	743	745	TCC	203;201;198	T;C;C,A	203;201;196,2	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5400	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3714	181.0	1	SNP	p	D95N	0	.	.	283	285	GAC	755	757	GAC	203;206;208	G;A;C	203;206;208	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5400	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3714	181.0	1	SNP	p	D95G	0	.	.	283	285	GAC	755	757	GAC	203;206;208	G;A;C	203;206;208	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	2020	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1907	132.4	1	SNP	p	G45D	1	.	.	133	135	GAC	762	764	GAC	227;228;229	G;A,G,C;C	227;226,1,1;229	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1150	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1558	92.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5286	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3523	187.1	1	SNP	p	D86N	0	.	.	256	258	GAC	880	882	GAC	207;206;208	G,C;A,C;C	206,1;205,1;208	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5286	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3523	187.1	1	SNP	p	S87I	0	.	.	259	261	AGT	883	885	AGT	210;209;210	A,C;G;T,G	209,1;209;209,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5286	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3523	187.1	1	SNP	p	S87W	0	.	.	259	261	AGT	883	885	AGT	210;209;210	A,C;G;T,G	209,1;209;209,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5286	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3523	187.1	1	SNP	p	S87R	0	.	.	259	261	AGT	883	885	AGT	210;209;210	A,C;G;T,G	209,1;209;209,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5286	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3523	187.1	1	SNP	p	S88P	0	.	.	262	264	TCC	886	888	TCC	212;210;210	T;C,A;C	212;209,1;210	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4398	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3120	175.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1797	1799	GGC	221;220;219	G;G,C;C	221;219,1;219	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4026	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	170.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1553	1555	GCA	278;277;275	G;C;A	278;277;275	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4026	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	170.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1556	1558	ATC	275;274;268	A;T;C	275;274;268	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4026	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	170.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1568	1570	GTG	265;261;261	G,T;T;G	263,1;260;260	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4026	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	170.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1568	1570	GTG	265;261;261	G,T;T;G	263,1;260;260	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4026	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	170.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2072	2074	ACC	225;223;225	A;C;C,T	225;223;224,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4026	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	170.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2126	2128	GCG	235;234;234	G;C,G;G,T,C	235;232,2;232,1,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4026	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	170.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2126	2128	GCG	235;234;234	G;C,G;G,T,C	235;232,2;232,1,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4026	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	170.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2249	2251	GGC	179;176;176	G;G;C	179;176;176	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4026	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	170.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2258	2260	GGC	186;187;188	G;G;C	186;187;188	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4026	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2956	170.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2276	2278	CCG	202;203;201	C,G;C;G	199,3;203;201	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5664	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	3291	213.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2778	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2393	144.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	803	803	C	216	C,A	215,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	E48G	NONSYN	142	144	GAA	568	570	GGA	200;200;203	G,A;G,C;A	199,1;199,1;203	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	V75I	NONSYN	223	225	GTT	649	651	ATT	233;231;231	A;T;T,A	233;231;230,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	T89S	NONSYN	265	267	ACC	691	693	AGC	245;245;244	A;G;C	245;245;244	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	V98I	NONSYN	292	294	GTC	718	720	ATC	248;248;248	A;T;C	248;248;248	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	.	MULTIPLE	358	359	AA	783	784	CG	209;209	C;G,C	209;208,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	.	MULTIPLE	361	362	GA	786	788	CAG	210;207;206	C;A,C;G,C	210;206,1;205,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	N122K	NONSYN	364	366	AAC	790	792	AAA	208;209;209	A;A;A	208;209;209	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	G140R	NONSYN	418	420	GGA	844	846	AGA	203;202;199	A,G;G;A	202,1;202;199	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	K143E	NONSYN	427	429	AAA	853	855	GAA	198;201;200	G;A;A,C	198;201;199,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	V151A	NONSYN	451	453	GTA	877	879	GCA	215;214;213	G;C;A	215;214;213	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	T213S	NONSYN	637	639	ACA	1063	1065	TCA	277;273;275	T;C,A;A	277;272,1;275	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1183	1185	CAA	215;212;212	C;A;A	215;212;212	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	.	INDELS	760	762	ACA	1187	1191	ATCAA	209;208;209;207;206	A;T,A;C,A;A;A	209;207,1;208,1;207;206	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	.	INDELS	763	764	TG	1194	1196	AGT	206;207;208	A;G;T	206;207;208	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1201	1203	GAT	220;220;219	G,T;A;T	219,1;220;219	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1309	1311	AGT	258;258;259	A;G;T	258;258;259	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1315	1317	GAC	270;275;276	G;A;C,T,A	270;275;274,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1318	1320	TAC	278;278;279	T,G;A;C	277,1;278;279	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	1	SNP	p	G120K	1	.	.	358	360	AAG	783	785	CGG	209;209;208	C;G,C;G	209;208,1;208	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	1	SNP	p	D121N	0	.	.	361	363	GAC	786	789	CGC	210;206;206	C;G,C;C,T	210;205,1;205,1	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2776	porB1b	1041	1041	97.14	porB1b.l15.c17.ctg.1	1720	199.8	1	SNP	p	A121D	1	.	.	361	363	GAC	786	789	CGC	210;206;206	C;G,C;C,T	210;205,1;205,1	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	270	porB3	990	162	93.83	porB3.l15.c30.ctg.1	164	51.1	0	.	p	.	0	S273T	NONSYN	817	819	TCG	62	64	ACT	67;67;67	A;C;T	67;67;67	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	270	porB3	990	162	93.83	porB3.l15.c30.ctg.1	164	51.1	0	.	p	.	0	D276S	NONSYN	826	828	GAT	71	73	AGT	67;67;67	A;G;T	67;67;67	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	270	porB3	990	162	93.83	porB3.l15.c30.ctg.1	164	51.1	0	.	p	.	0	K278D	NONSYN	832	834	AAA	77	79	GAC	67;67;67	G;A;C,A	67;67;66,1	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	270	porB3	990	162	93.83	porB3.l15.c30.ctg.1	164	51.1	0	.	p	.	0	R279Y	NONSYN	835	837	CGC	80	82	TAC	67;67;67	T;A;C	67;67;67	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9156	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	5188	219.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2152	2154	AAT	258;258;261	A,G;A;T,A	257,1;258;260,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1458	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1347	134.7	1	SNP	p	V57M	1	.	.	169	171	ATG	681	683	ATG	263;265;264	A;T;G	263;265;264	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
